Leerink Partners Issues Pessimistic Forecast for Abbott Laboratories (NYSE:ABT) Stock Price

Abbott Laboratories (NYSE:ABT) had its price objective decreased by analysts at Leerink Partners from $136.00 to $119.00 in a report issued on Friday,MarketScreener reports. The firm presently has a “market perform” rating on the healthcare product maker’s stock. Leerink Partners’ price target points to a potential upside of 8.86% from the stock’s current price.

Several other brokerages also recently weighed in on ABT. Oppenheimer lowered their price target on shares of Abbott Laboratories from $140.00 to $132.00 and set an “outperform” rating on the stock in a report on Friday, January 23rd. Daiwa Capital Markets lowered their target price on shares of Abbott Laboratories from $136.00 to $113.00 and set an “outperform” rating on the stock in a research note on Friday. The Goldman Sachs Group dropped their target price on shares of Abbott Laboratories from $152.00 to $140.00 and set a “buy” rating for the company in a report on Friday, January 23rd. Weiss Ratings cut Abbott Laboratories from a “buy (b-)” rating to a “hold (c+)” rating in a report on Monday, January 26th. Finally, Freedom Capital raised Abbott Laboratories from a “hold” rating to a “strong-buy” rating in a research note on Thursday. Two analysts have rated the stock with a Strong Buy rating, sixteen have given a Buy rating and four have issued a Hold rating to the company’s stock. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $138.40.

Abbott Laboratories Price Performance

NYSE ABT opened at $109.31 on Friday. The business’s fifty day moving average is $122.77 and its 200 day moving average is $127.46. Abbott Laboratories has a fifty-two week low of $105.27 and a fifty-two week high of $141.23. The company has a debt-to-equity ratio of 0.23, a quick ratio of 1.24 and a current ratio of 1.70. The company has a market capitalization of $190.08 billion, a PE ratio of 29.39, a price-to-earnings-growth ratio of 1.69 and a beta of 0.72.

Abbott Laboratories (NYSE:ABT) last posted its quarterly earnings data on Thursday, January 22nd. The healthcare product maker reported $1.50 EPS for the quarter, hitting the consensus estimate of $1.50. The firm had revenue of $11.46 billion for the quarter, compared to the consensus estimate of $11.80 billion. Abbott Laboratories had a return on equity of 17.94% and a net margin of 14.72%.The business’s revenue for the quarter was up 4.4% compared to the same quarter last year. During the same quarter last year, the company earned $1.34 earnings per share. Abbott Laboratories has set its Q1 2026 guidance at 1.120-1.180 EPS and its FY 2026 guidance at 5.550-5.800 EPS. Sell-side analysts predict that Abbott Laboratories will post 5.14 earnings per share for the current year.

Institutional Investors Weigh In On Abbott Laboratories

A number of hedge funds have recently made changes to their positions in ABT. IMG Wealth Management Inc. raised its holdings in shares of Abbott Laboratories by 759.1% during the 2nd quarter. IMG Wealth Management Inc. now owns 189 shares of the healthcare product maker’s stock worth $26,000 after acquiring an additional 167 shares in the last quarter. Harbor Capital Advisors Inc. bought a new stake in Abbott Laboratories in the fourth quarter worth $27,000. Cloud Capital Management LLC purchased a new stake in Abbott Laboratories during the third quarter valued at $29,000. Guerra Advisors Inc bought a new position in Abbott Laboratories during the third quarter valued at $31,000. Finally, Anfield Capital Management LLC grew its stake in shares of Abbott Laboratories by 81.3% in the 2nd quarter. Anfield Capital Management LLC now owns 232 shares of the healthcare product maker’s stock worth $32,000 after buying an additional 104 shares in the last quarter. 75.18% of the stock is currently owned by hedge funds and other institutional investors.

Key Stories Impacting Abbott Laboratories

Here are the key news stories impacting Abbott Laboratories this week:

• Positive Sentiment: Abbott announced a portfolio reset tied to a deal with Exact Sciences that refocuses its cancer diagnostics strategy — investors appear to view the move as a strategic repositioning that could improve longer‑term growth in diagnostics. Abbott Laboratories Resets Portfolio With Exact Sciences Cancer Diagnostics Deal
• Positive Sentiment: Freedom Capital upgraded ABT from “hold” to “strong‑buy,” a bullish vote that can attract buy‑side interest and support near‑term buying pressure. Freedom Capital upgrade (Zacks)
• Neutral Sentiment: Analyst commentary and feature pieces are framing Abbott as a steady, dividend‑oriented healthcare name, which reinforces income investor interest but is unlikely to drive a large repricing on its own. Looking for Passive Income in 2026? 3 Dividend Kings to Buy Hand Over Fist
• Neutral Sentiment: Coverage pieces and analyst‑call writeups summarize Q4 takeaways and evolving price targets; useful for longer‑term positioning but largely reiterative. How New Price Targets Are Shaping The Evolving Story For Abbott Laboratories (ABT) 5 Insightful Analyst Questions From Abbott’s Q4 Call
• Neutral Sentiment: Updates projecting “decent organic sales growth” for 2026 support baseline expectations for revenue improvement but are not a catalyst by themselves. Decent organic sales growth expected for Abbott Laboratories (ABT) in 2026
• Negative Sentiment: Daiwa Capital Markets lowered its price target to $113 (from $136) while keeping an “outperform” call — a downward PT revision that can cool momentum and signals reduced near‑term upside expectations. Daiwa Securities adjusts Abbott PT to $113
• Negative Sentiment: Leerink Partners cut its target to $119 (from $136) and moved to “market perform,” another analyst downgrade that adds pressure and contributes to today’s mixed tone. Leerink Partners adjusts Abbott PT to $119 TickerReport coverage

Abbott Laboratories Company Profile

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.

In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.